Literature DB >> 7512926

Involvement of central serotonergic pathways in analgesia elicited by salmon calcitonin in the mouse.

M I Colado1, M J Ormazabal, C Goicoechea, F Lopez, M J Alfaro, M I Martin.   

Abstract

The contribution of central serotonergic pathways to the analgesic activity induced by salmon calcitonin in the writhing test was investigated. Salmon calcitonin was administered to mice after lesioning of the ascending and descending serotonergic pathways by means of i.p. administration of p-chloroamphetamine (40 mg/kg, for 2 days) or p-chlorophenylalanine (300 mg/kg, for 3 days). The analgesic effect induced by salmon calcitonin at the doses of 10 and 20 IU/kg was not evident in mice previously treated with p-chloroamphetamine or p-chlorophenylalanine. However, the analgesic effect of salmon calcitonin 40 IU/kg was not significantly modified by p-chloroamphetamine or p-chlorophenylalanine pretreatment. Salmon calcitonin did not alter the depletion of 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid after p-chloroamphetamine or p-chlorophenylalanine administration. Similarly, this hormone did not change the NSD 1015-induced accumulation of 5-hydroxytryptophan or the tranylcypromine-induced accumulation of 5-HT. These results indicate that although salmon calcitonin does not influence the synthesis and metabolism of 5-HT, it does require the integrity of the serotonergic system in order to cause analgesia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512926     DOI: 10.1016/0014-2999(94)90175-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

Review 2.  Salmon calcitonin: a review of current and future therapeutic indications.

Authors:  C H Chesnut; M Azria; S Silverman; M Engelhardt; M Olson; L Mindeholm
Journal:  Osteoporos Int       Date:  2007-12-11       Impact factor: 4.507

Review 3.  Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.

Authors:  Morten A Karsdal; Mette J Nielsen; Jannie M Sand; Kim Henriksen; Federica Genovese; Anne-Christine Bay-Jensen; Victoria Smith; Joanne I Adamkewicz; Claus Christiansen; Diana J Leeming
Journal:  Assay Drug Dev Technol       Date:  2012-10-09       Impact factor: 1.738

4.  Efficacy of Ultrasound-Guided Caudal Epidural Calcitonin for Patients with Failed Back Surgery Syndrome.

Authors:  El-Sayed M El-Emam; Enas A Abd El Motlb
Journal:  Anesth Essays Res       Date:  2019-08-02

5.  Anti-nociceptive effects of elcatonin injection for postmenopausal women with back pain: a randomized controlled trial.

Authors:  Shota Ikegami; Mikio Kamimura; Shigeharu Uchiyama; Hiroyuki Nakagawa; Hiroyuki Hashidate; Kenji Takahara; Jun Takahashi; Hiroyuki Kato
Journal:  Open Orthop J       Date:  2010-03-04

6.  Analgesic effects of calcitonin on radicular pain in male rats.

Authors:  Yoshinori Terashima; Tsuneo Takebayashi; Shunsuke Jimbo; Izaya Ogon; Tatsuya Sato; Nobutoshi Ichise; Noritsugu Tohse; Toshihiko Yamashita
Journal:  J Pain Res       Date:  2019-01-03       Impact factor: 3.133

7.  Calcitonin attenuates cartilage degeneration and nociception in an experimental rat model of osteoarthritis: role of TGF-β in chondrocytes.

Authors:  Zhi-Hong Wen; Chi-Chieh Tang; Yi-Chen Chang; Shi-Ying Huang; Yen-You Lin; Shih-Peng Hsieh; Hsin-Pai Lee; Sung-Chun Lin; Wu-Fu Chen; Yen-Hsuan Jean
Journal:  Sci Rep       Date:  2016-06-27       Impact factor: 4.379

Review 8.  Mechanisms of the analgesic effect of calcitonin on chronic pain by alteration of receptor or channel expression.

Authors:  Akitoshi Ito; Megumu Yoshimura
Journal:  Mol Pain       Date:  2017 Jan-Dec       Impact factor: 3.395

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.